Study participants
valve disease, cancer, LV dysfunction, non-ischemic cardiomyopathy, HIV or HTLV-1
CANCER, DISEASE, NON-ISCHEMIC CARDIOMYOPATHY, SYPHILIS, HEPATITIS C, ST ELEVATION MYOCARDIAL INFARCTION, AUTOIMMUNE DISEASE
Seventy patients hospitalized at Al-Zahra, Nemazee, or Faghihi Hospital (Shiraz, Iran) following an anterior ST elevation myocardial infarction (STEMI) and treated with a successful primary percutaneous coronary intervention (PCI) were included in this study. Inclusion criteria consisted of: 1—patients were 20–60 years old, 2—had their MI 3–7 days earlier, 3—had an echocardiographic LVEF < 40%. Exclusion criteria were: 1—prior history of an anterior MI, 2—regional wall motion abnormalities in the non-infarct region, 3—history of coronary artery bypass graft (CABG) surgery, 4—significant valve disease (stenosis/regurgitation grade ≥ 2), 5—alternative etiology of LV dysfunction (non-ischemic cardiomyopathy, 6—anthracycline therapy, 7—regular ethanol abuse > 6 oz. ethanol/day), 8—poor echocardiography window, 9—active syphilis, 10—hepatitis B, hepatitis C, HIV or HTLV-1, 11—terminal disease or cancer, 12—history of a bone marrow transplant, or an autoimmune disease, 13—being pregnant.